Ftse Mib
34.600,00
-0,65%
DAX
18.726,76
-0,21%
S&P 500
5.315,05
0,13%
NASDAQ
16.807,10
0,07%
Bitcoin
69.876,44
-2,20%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NYSE Aventis New Ads (AVE) Aventis New Ads (AVE) Notizie

AVE

Aventis (AVE)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:AVE
DataOraFonteTitoloSimboloCompagnia
15/10/200423:03PR Newswire (US)Rhone-Poulenc Overseas Limited Announces Redemption of All Outstanding Cumulative Guaranteed Preference Shares, Series ANYSE:AVEAventis New Ads
04/10/200421:44PR Newswire (US)Aventis Ships 30 Million Doses of Influenza Vaccine to Health-Care ProvidersNYSE:AVEAventis New Ads
22/09/200423:23PR Newswire (US)Advisory Panel Recommends FDA Licensure of Aventis' Menactra(TM) Vaccine for Protection Against Meningococcal DiseaseNYSE:AVEAventis New Ads
21/09/200415:30PR Newswire (US)Aventis Named to List of Top 100 Companies for Working MothersNYSE:AVE
16/09/200409:00PR Newswire (US)The sanofi-aventis Group Thanks Its Team Members and Shareholders and Launches Its New Visual IdentityNYSE:AVE
14/09/200415:30PR Newswire (US)Coley Pharmaceutical Group Receives Payment From Aventis for Clinical Milestone in Collaboration on Allergic Respiratory DiseaseNYSE:AVEAventis New Ads
19/08/200415:00PR Newswire (US)FDA Approves Taxotere(R) for the Treatment of Women with Early Stage Breast CancerNYSE:AVEAventis New Ads
11/08/200417:39PR Newswire (US)Aventis Submits Application for FDA Licensure of ADACEL(TM) Vaccine for Prevention of Tetanus, Diphtheria and Pertussis in AdoleNYSE:AVEAventis New Ads
06/08/200402:02PR Newswire (US)Ventiv Health Announces Sales and Marketing Agreement with AventisNYSE:AVEAventis New Ads
03/08/200420:58PR Newswire (US)FDA Approves Sculptra(TM) (Injectable Poly-L-Lactic Acid)NYSE:AVEAventis New Ads
28/07/200421:31PR Newswire (US)Aventis Reports Second-Quarter and First-Half Results for 2004NYSE:AVEAventis New Ads
27/07/200417:29PR Newswire (US)Aventis to Move Forward With Reissuance Process for Contested Lovenox PatentNYSE:AVE
07/07/200415:00PR Newswire (US)New Data Confirm Lovenox(R) is an Effective Antithrombotic for Treatment of Acute Coronary SyndromesNYSE:AVE
23/06/200416:50PR Newswire (US)Sanofi-Synthelabo's Offer for Aventis Expiration Date of OffersNYSE:AVE
14/06/200417:43PR Newswire (US)Sanofi-Synthelabo's Offer for Aventis; Adjustment of Offer Terms on Approval of Aventis DividendNYSE:AVE
07/06/200419:00PR Newswire (US)Two Landmark Studies Show That Taxotere(R) Significantly Improves Survival in Men With Prostate CancerNYSE:AVEAventis New Ads
05/06/200416:00PR Newswire (US)Investigators Report Taxotere(R) Offers Significant Survival Benefits for Head and Neck Cancer PatientsNYSE:AVEAventis New Ads
28/05/200419:00PR Newswire (US)Genta and Aventis Announce Termination of Genasense(TM) Expanded Access Program in MelanomaNYSE:AVEAventis New Ads
27/05/200409:00PR Newswire (US)Aventis and U.S. NIH Enter Into Pandemic Influenza Vaccine AgreementNYSE:AVE
26/05/200417:05PR Newswire (US)Sanofi-Synthelabo's Offer for Aventis U.S. Offer Extended to Wednesday, June 30, 2004NYSE:AVE
26/05/200415:00PR Newswire (US)Two Landmark Studies of Taxotere(R) in Prostate Cancer Highlighted in American Society of Clinical Oncology Plenary SessionNYSE:AVEAventis New Ads
23/05/200419:15PR Newswire (US)Data Show Once-Daily Alvesco(R) (ciclesonide) Has No Effect on HPA-Axis Function in Asthma PatientsNYSE:AVE
23/05/200419:15PR Newswire (US)Surveillance Study Finds Newly-Approved Antibiotic KETEK(R) (telithromycin) Tablets 99% Effective In Vitro Against StreptococcusNYSE:AVE
19/05/200421:39PR Newswire (US)Aventis Receives FDA Approval for Taxotere(R) in Prostate CancerNYSE:AVEAventis New Ads
18/05/200415:01PR Newswire (US)Aventis Receives Priority Review Designation for the Registrational Application to Support the Use of Taxotere(R) in Women withNYSE:AVE
05/05/200417:12PR Newswire (US)Sanofi-Synthelabo's Offer for AventisNYSE:AVE
03/05/200421:52PR Newswire (US)FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced MelanomaNYSE:AVEAventis New Ads
30/04/200421:55PR Newswire (US)Aventis Pasteur Statement on New Influenza Immunization Recommendations for Infants, Young Children and Their Close ContactsNYSE:AVE
29/04/200420:03PR Newswire (US)Aventis Reports First-Quarter Results for 2004NYSE:AVE
27/04/200416:52PR Newswire (US)Approval by The European Commission of the Planned Acquisition of Aventis By Sanofi-SynthelaboNYSE:AVE
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:AVE

La tua Cronologia

COIN
SSXCUSD
Somesing Exchange
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network